Library · Metabolic & weight · Treatment of obesity and metabolic disorders
Cagrilintide
NNC0174-0833, AM833, NN9838
Long-acting amylin analog in Phase 3 development for weight management, mimicking amylin’s satiety and gastric-slowing effects. Being developed alone and combined with semaglutide (CagriSema) for greater weight loss than either drug alone.
Research score 85/100. Reference only, not a dose.
- Appetite Suppression
- Metabolic Enhancement
- Blood Sugar Control
- GLP-1 Agonist
- Gut Health
- US status
- Investigational
- Approval
- Phase 2/3 Clinical Trial
- Evidence
- Phase 3 trials (REDEFINE). Often studied with semaglutide (CagriSema).
- Research score
- 85 / 100
- Indication
- Obesity/Weight Management
- Origin
- Denmark
- Source category
- Digestive System
- Status group
- Investigational
Mechanism
Agonizes calcitonin receptors, activating cAMP/PKA signaling in hypothalamic neurons to boost satiety, while slowing gastric emptying and suppressing after-meal glucagon; structural modifications extend its half-life for infrequent dosing.
Safety file
Nausea and vomiting are common; no increased pancreatitis signal so far, and cardiovascular profile appears favorable.
- Nausea
- Decreased appetite
- Injection site reactions
- Gastrointestinal disturbances